Inventor · disambiguated record
Tatiana Shelekhin
Also filed as: SHELEKHIN TATIANA · SHELEKHIN TATIANA E
24 granted patents·10 pending applications·191 citations·filing 1999–2024
95Inventor score
Files withFORMA THERAPEUTICS INC10BAYER PHARMACEUTICALS CORP4NOVO NORDISK HEALTHCARE AG4BAYER HEALTHCARE LLC3VALO EARLY DISCOVERY INC3
Top patents by PatentIndex Score
34 records- 0198US10472371B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 12, 2019·13 cites·3 claims
- 0298US10208052B1Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2018·Granted Feb 19, 2019·36 cites·10 claims
- 0397US11980611B2Treating sickle cell disease with a pyruvate kinase R activating compoundNOVO NORDISK HEALTHCARE AG·Filed 2022·Granted May 14, 2024·3 cites·4 claims
- 0497US11649242B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2021·Granted May 16, 2023·5 cites·4 claims
- 0597US11396513B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2020·Granted Jul 26, 2022·6 cites·8 claims
- 0696US11014927B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsFORMA THERAPEUTICS INC·Filed 2018·Granted May 25, 2021·6 cites·3 claims
- 0796US10836771B2Compositions for activating pyruvate kinaseFORMA THERAPEUTICS INC·Filed 2019·Granted Nov 17, 2020·7 cites·2 claims
- 0892US7517874B2Substituted imidazo[1,5-a][1,4]diazepines and imidazo[1,5-a]pyrazines as cannabinoid receptor agonists for the treatment of painCARA THERAPEUTICS INC·Filed 2008·Granted Apr 14, 2009·42 cites·20 claims
- 0990US2024391922A1Pyrrolopyrrole compositions as pyruvate kinase (pkr) activatorsNovo Nordisk Heathcare AG·Filed 2024·Application pending·0 cites
- 1088US12071440B2Pyrrolopyrrole compositions as pyruvate kinase (PKR) activatorsNOVO NORDISK HEALTHCARE AG·Filed 2023·Granted Aug 27, 2024·0 cites·4 claims
- 1186US6660752B22,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonistsBAYER PHARMACEUTICALS CORP·Filed 2002·Granted Dec 9, 2003·24 cites·30 claims
- 1283US10889592B2Thienopyrazine carboxamides as ubiquitin-specific protease inhibitorsVALO EARLY DISCOVERY INC·Filed 2017·Granted Jan 12, 2021·2 cites·28 claims
- 1383US6469065B1Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of useNITROMED INC·Filed 1999·Granted Oct 22, 2002·33 cites·19 claims
- 1482US11524966B1Carboxamides as ubiquitin-specific protease inhibitorsVALO EARLY DISCOVERY INC·Filed 2018·Granted Dec 13, 2022·2 cites·15 claims
- 1580US10913753B2Thienopyridine carboxamides as ubiquitin-specific protease inhibitorsFORMA THERAPEUTICS INC·Filed 2017·Granted Feb 9, 2021·2 cites·20 claims
- 1677US8431695B2Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseasesO'CONNOR STEPHEN·Filed 2006·Granted Apr 30, 2013·5 cites·6 claims
- 1775US12053458B2Treating sickle cell disease with a pyruvate kinase R activating compoundNOVO NORDISK HEALTHCARE AG·Filed 2019·Granted Aug 6, 2024·0 cites·12 claims
- 1871US12122778B2Activating pyruvate kinase RNOVO NORDISK HEALTHCARE AG·Filed 2019·Granted Oct 22, 2024·0 cites·19 claims
- 1968US8859538B2Uses of substituted imidazoheterocyclesBECKETT R PAUL·Filed 2010·Granted Oct 14, 2014·3 cites·14 claims
- 2066US6919371B22,6-substituted chroman derivatives useful as beta-3 adrenoreceptor agonistsBAYER PHARMACEUTICALS CORP·Filed 2003·Granted Jul 19, 2005·2 cites·24 claims
- 2162US11325917B2Thienopyrazine carboxamides as ubiquitin-specific protease inhibitorsVALO HEALTH INC·Filed 2020·Granted May 10, 2022·0 cites·20 claims
- 2257US12252490B2Inhibiting deubiquitinase USP25 and USP28VALO HEALTH INC·Filed 2019·Granted Mar 18, 2025·0 cites·15 claims
- 2355US8431565B2Substituted imidazoheterocyclesBECKETT R PAUL·Filed 2008·Granted Apr 30, 2013·0 cites·22 claims
- 2454US2005187222A1Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compoundsNITROMED INC·Filed 2005·Application pending·0 cites
- 2554US2021346356A1Inhibiting ubiquitin specific peptidase 9xFORMA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2651US7759376B2Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesityBAYER HEALTHCARE LLC·Filed 2005·Granted Jul 20, 2010·0 cites·9 claims
- 2750US12162888B2Carboxamides as ubiquitin-specific protease inhibitorsVALO EARLY DISCOVERY INC·Filed 2019·Granted Dec 10, 2024·0 cites·15 claims
- 2850US2010016295A1Preparation and Use of Biphenyl Amino Acid Derivatives for the Treatment of ObesityBAYER HEALTHCARE LLC·Filed 2006·Application pending·0 cites
- 2948US2022041597A1Inhibiting ubiquitin specific peptidase 9xFORMA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3046US2023065368A1Inhibiting ubiquitin specific peptidase 9xFORMA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3146US2006063760A1Hydroxamic acids useful in the treatment of hyper-proliferative disordersBAYER PHARMACEUTICALS CORP·Filed 2004·Application pending·0 cites
- 3246US2002143007A1Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of useFiled 2002·Application pending·0 cites
- 3342US2011118302A1Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesityBAYER PHARMACEUTICALS CORP·Filed 2010·Application pending·0 cites
- 3441US2010234307A1Preparation and use of biphenyl amino acid derivatives for the treatment of obesityBAYER HEALTHCARE LLC·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tatiana Shelekhin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →